Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe.
Adequate balance sheet with limited growth.
Share Price & News
How has Avinger's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AVGR's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: AVGR underperformed the US Medical Equipment industry which returned 11.1% over the past year.
Return vs Market: AVGR underperformed the US Market which returned 8.9% over the past year.
Price Volatility Vs. Market
How volatile is Avinger's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StAvinger, Inc. Just Reported, And Analysts Assigned A US$2.38 Price Target
4 months ago | Simply Wall StHow Avinger, Inc. (NASDAQ:AVGR) Can Impact Your Portfolio Volatility
1 year ago | Simply Wall StHow Does Avinger Inc (NASDAQ:AVGR)’s Prospect Stack Up To Its Healthcare Peers?
Is Avinger undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AVGR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AVGR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AVGR is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: AVGR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AVGR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AVGR is good value based on its PB Ratio (1.6x) compared to the US Medical Equipment industry average (3.9x).
How is Avinger forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AVGR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AVGR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AVGR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AVGR's revenue (26.1% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: AVGR's revenue (26.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AVGR's Return on Equity is forecast to be high in 3 years time
How has Avinger performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AVGR is currently unprofitable.
Growing Profit Margin: AVGR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AVGR is unprofitable, but has reduced losses over the past 5 years at a rate of 12.4% per year.
Accelerating Growth: Unable to compare AVGR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVGR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (7.2%).
Return on Equity
High ROE: AVGR has a negative Return on Equity (-459.3%), as it is currently unprofitable.
How is Avinger's financial position?
Financial Position Analysis
Short Term Liabilities: AVGR's short term assets ($16.1M) exceed its short term liabilities ($14.5M).
Long Term Liabilities: AVGR's short term assets ($16.1M) exceed its long term liabilities ($3.9M).
Debt to Equity History and Analysis
Debt Level: AVGR's debt to equity ratio (212.5%) is considered high.
Reducing Debt: AVGR's debt to equity ratio has increased from 69.7% to 212.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AVGR has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: AVGR is forecast to have sufficient cash runway for 7 months based on free cash flow estimates, but has since raised additional capital.
What is Avinger's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AVGR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AVGR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AVGR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AVGR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AVGR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jeff Soinski (57yo)
Mr. Jeffrey M. Soinski, also known as Jeff, has been Chief Executive Officer, President and Director of Avinger, Inc. (“Avinger”) since December 29, 2014. From Avinger’s formation in September 2009 until t ...
CEO Compensation Analysis
Compensation vs Market: Jeff's total compensation ($USD607.41K) is about average for companies of similar size in the US market ($USD577.87K).
Compensation vs Earnings: Jeff's compensation has been consistent with company performance over the past year.
|Chief Financial Officer||2yrs||US$431.95k||0.13% $17.8k|
|Chief Technology Officer||6.67yrs||US$426.93k||0.14% $18.6k|
|Chief Operating Officer||no data||no data||no data|
Experienced Management: AVGR's management team is seasoned and experienced (5.5 years average tenure).
|Independent Director||9.25yrs||US$140.00k||0.016% $2.1k|
|Non-Executive Chairman & Lead Independent Director||2.5yrs||US$157.50k||0.016% $2.1k|
|Independent Director||0.50yr||no data||no data|
Experienced Board: AVGR's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 358.3%.
Avinger, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Avinger, Inc.
- Ticker: AVGR
- Exchange: NasdaqCM
- Founded: 2007
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$13.240m
- Shares outstanding: 29.42m
- Website: https://www.avinger.com
Number of Employees
- Avinger, Inc.
- 400 Chesapeake Drive
- Redwood City
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AVGR||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Jan 2015|
|VG2B||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 2015|
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company’s lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. The company markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was founded in 2007 and is headquartered in Redwood City, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/06 05:43|
|End of Day Share Price||2020/06/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.